Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2b randomized, double-blind, placebo-controlled study of Nitric-oxide in Pulmonary-hypertension patients associated with Chronic Obstructive Pulmonary Disease

Trial Profile

Phase 2b randomized, double-blind, placebo-controlled study of Nitric-oxide in Pulmonary-hypertension patients associated with Chronic Obstructive Pulmonary Disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2018 According to the Bellerophon Therapeutics media release, the company expects to initiate this trial in 2019.
    • 17 May 2018 According to the Bellerophon Therapeutics media release, company in conjunction with its steering committee finalized the design of this trial and agreement with the FDA has been reached on the design of this trial.
    • 17 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top